At the news
? NEUTRALIMPACT 4/10 8-K filed Sep 3, 2026 at 08:47 ET
AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics, adding late-stage immunology assets zumilokibart (atopic dermatitis) and APG273 (asthma). AbbVie reaffirmed its FY2026 adjusted EPS guidance of $13.87-$14.07 and Q3 guidance of $3.84-$3.88, with the deal expected to dilute EPS by $0.14 in 2026 and $0.46 in 2027 before becoming accretive in 2032.
- Acquisition of Apogee Therapeutics completed for $135.11 per share in cash, total equity value ~$10.9 billion
- Apogee's lead asset zumilokibart (IL-13 mAb) is in Phase 2 for atopic dermatitis with potential best-in-category profile
- Pipeline includes APG273 (IL-13 + TSLP combination) in development for asthma
- AbbVie reaffirms FY2026 adjusted diluted EPS guidance range $13.87-$14.07
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access